Lupin established a partnership with Foncoo on Wednesday, which specializes in supplying pharmaceutical treatments to treat Central Nervous System disorders. Lupin said the collaboration with Fonco is for providing high-quality generic and complex generic medicines to patients across the globe.
“Lupin continues to invest in key growth markets. With China’s growing commitment to affordable and accessible healthcare, Lupin is committed to serving the healthcare needs of the Chinese population by providing high-quality generic and complex generic products. We are very excited about our partnership with Foncoo. We will continue exploring additional partnership opportunities in China to leverage our global portfolio including complex generics and specialty medicines,”Dr. Fabrice Egros, President, Growth Markets, Lupin said.
“Foncoo’s successful experiences on importing registration and marketing of the generic formulations and Lupin’s strong capability of making high-quality medicines make us perfect match to each other and our collaboration will have a bright future most likely. We expect that the successful launch of our first product in China will come smoothly and soon. We will also continue exploring more opportunities to work with Lupin for providing more and more high-valued and complex medicines to the Chinese physicians and patients,”Mr. Peng Yan, General Manager, Foncoo said.
This is Lupin’s first partnership in China, and it demonstrates the company’s dedication to provide patients around the world with high-quality generic and complex generic medications.